Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207776 | 0.83 | — | — | |
| SCHEMBL11688163 | 0.77 | CA1 (0.69) | CA1CA2CA7 | |
| SCHEMBL4141702 | 0.77 | — | — | |
| SCHEMBL196906 | 0.74 | LMNA (0.42) | — | |
| SCHEMBL1377831 | 0.72 | HSD17B10 (0.40) | — | |
| SCHEMBL2723676 | 0.71 | — | — | |
| SCHEMBL391423 | 0.71 | — | — | |
| SCHEMBL1486989 | 0.71 | — | — | |
| SCHEMBL2325561 | 0.70 | CA1 (0.40) | CA1CA2 | |
| SCHEMBL21356989 | 0.69 | CA1 (1.00) | CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112752756-B | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2024-06-25 | — | — | CN | claimed |
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-11-03 | — | — | US | claimed |
| CN-112752756-A | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2021-05-04 | — | — | CN | claimed |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | claimed |
| EP-3790877-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | claimed |
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-02-02 | — | — | US | claimed |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-03 | — | — | US | claimed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | claimed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | claimed |
| CN-1976916-A | Selected CGRP-antagonists, method for the production thereof and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-06-06 | — | — | CN | claimed |
| EP-1740577-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| EP-1732917-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-20 | — | — | EP | claimed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | claimed |
| WO-2005103037-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| WO-2005092880-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | claimed |
| EP-1102789-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008046-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CA1 4089/4885CA2 4677/4885CA7 4055/4885 |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CA1 4089/4885CA2 4677/4885CA7 4055/4885 |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CA1 4089/4885CA2 4677/4885CA7 4055/4885 |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CA1 4089/4885CA2 4677/4885CA7 4055/4885 |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CA1 1988/4885CA2 981/4885CA7 1924/4885 |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CA1 1869/4885CA2 814/4885CA7 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.